IL178802A0 - Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases - Google Patents

Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases

Info

Publication number
IL178802A0
IL178802A0 IL178802A IL17880206A IL178802A0 IL 178802 A0 IL178802 A0 IL 178802A0 IL 178802 A IL178802 A IL 178802A IL 17880206 A IL17880206 A IL 17880206A IL 178802 A0 IL178802 A0 IL 178802A0
Authority
IL
Israel
Prior art keywords
viral
prevention
compositions
treatment
methods
Prior art date
Application number
IL178802A
Other languages
English (en)
Original Assignee
Avirid Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avirid Inc filed Critical Avirid Inc
Publication of IL178802A0 publication Critical patent/IL178802A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
IL178802A 2004-04-14 2006-10-22 Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases IL178802A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56193404P 2004-04-14 2004-04-14
PCT/US2005/012532 WO2005115444A2 (en) 2004-04-14 2005-04-14 Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases

Publications (1)

Publication Number Publication Date
IL178802A0 true IL178802A0 (en) 2007-03-08

Family

ID=35451407

Family Applications (1)

Application Number Title Priority Date Filing Date
IL178802A IL178802A0 (en) 2004-04-14 2006-10-22 Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases

Country Status (7)

Country Link
US (2) US9592277B2 (cg-RX-API-DMAC7.html)
EP (1) EP1734991A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007532666A (cg-RX-API-DMAC7.html)
AU (2) AU2005247298B8 (cg-RX-API-DMAC7.html)
CA (1) CA2604243C (cg-RX-API-DMAC7.html)
IL (1) IL178802A0 (cg-RX-API-DMAC7.html)
WO (1) WO2005115444A2 (cg-RX-API-DMAC7.html)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US9248166B2 (en) 2003-07-14 2016-02-02 Cls Therapeutics Limited Method for treating oncological diseases
US8710012B2 (en) * 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
WO2006130034A1 (fr) * 2005-04-25 2006-12-07 Dmitry Dmitrievich Genkin Procede pour prolonger la duree de vie d'animaux ou de l'humain
EP1734991A4 (en) * 2004-04-14 2012-10-24 Avirid Inc COMPOSITIONS COMPRISING MODIFIED NUCLEASES DIRECTED AGAINST VIRAL NUCLEIC ACIDS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES
US20090011004A1 (en) * 2005-12-30 2009-01-08 Philadelphia Health & Education Corp., D/B/A/ Drexel University Of College Of Medicine Improved carriers for delivery of nucleic acid agents to cells and tissues
JP2009526045A (ja) * 2006-02-10 2009-07-16 デルマゲン アクティエボラーグ 新規抗菌ペプチド及びその使用
US8840882B2 (en) * 2006-06-23 2014-09-23 Quintessence Biosciences, Inc. Modified ribonucleases
CA2662520A1 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties
EP2095825B8 (en) * 2006-11-28 2012-03-28 CLS Therapeutics Limited Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
WO2011031467A1 (en) * 2009-08-25 2011-03-17 Wayne State University Anti-cancer therapeutic strategy to overcome cancer resistance and to enable tailoring treatment to patients
GB0922066D0 (en) 2009-12-17 2010-02-03 Univ Belfast Modulator
EP2525835A4 (en) * 2010-01-18 2016-01-20 Univ Texas METHOD AND COMPOSITION FOR PARTICLE-CONTROLLED MEDICAMENTAL OUTPUT IN CANCER CELLS
KR101341640B1 (ko) * 2010-02-05 2013-12-16 한국전자통신연구원 단백질 미세 구조 분석 방법 및 단백질 미세 구조 분석용 어레이
US8981044B2 (en) * 2010-04-21 2015-03-17 National University Corporation Hokkaido University Lipid membrane structure having intranuclear migrating property
EP2490021A1 (en) * 2011-02-18 2012-08-22 Biotempt B.V. Modulators of PRR and GPCR signalling
WO2013126872A1 (en) * 2012-02-24 2013-08-29 Wayne State University Anti-cancer therapeutic strategy to overcome cancer resistance and to enable tailoring treatment to patients
JP2015527296A (ja) 2012-03-26 2015-09-17 アメリカ合衆国 哺乳動物細胞へのパッケージングされたｒｎａの新規の送達
WO2014113493A1 (en) 2013-01-16 2014-07-24 Emory University Cas9-nucleic acid complexes and uses related thereto
EP2969011A4 (en) * 2013-03-15 2017-03-01 Techulon Inc. Rapidly adaptable nano therapeutics for treatment of infectious disease
EP3035917A4 (en) * 2013-08-23 2017-03-01 Rutgers, the State University of New Jersey Biologically active synthetic nanoparticle constructs and methods of use therof
US11306326B2 (en) 2013-08-23 2022-04-19 Rutgers, The State University Of New Jersey Biologically active synthetic nanoparticle constructs and methods of use thereof
KR102467982B1 (ko) 2013-12-16 2022-11-16 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Vlp-레플리콘을 이용한 클래스 ii mhc 항원의 전달에 의한 암 면역요법
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
KR20170080579A (ko) 2014-10-01 2017-07-10 플랜트 헬스 케어, 인코포레이티드 파괴된 과민성 반응 박스를 갖는 유발제 펩티드 및 그의 용도
JP2017530197A (ja) 2014-10-01 2017-10-12 プラント ヘルス ケア インコーポレイテッド 過敏感反応エリシターペプチド及びその使用
RU2726131C2 (ru) 2015-05-22 2020-07-09 Дмитрий Дмитриевич Генкин Внеклеточная днк в качестве терапевтической мишени при нейродегенерации
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
JP7341451B2 (ja) 2016-02-01 2023-09-11 エピアクシス セラピューティクス プロプライアタリー リミティド タンパク質性化合物とその利用
CN111587120A (zh) 2017-11-08 2020-08-25 艾比克斯治疗私人有限公司 免疫原性组合物及其用途
WO2019099685A1 (en) 2017-11-15 2019-05-23 Rutgers, The State University Of New Jersey Biodegradable hybrid inorganic nanoscaffolding materials and methods of use and manufacture thereof
CN111712468A (zh) 2017-12-22 2020-09-25 北卡罗莱纳州立大学 聚合物荧光团、包含其的组合物及制备和使用其的方法
EP3740581A4 (en) 2018-01-16 2021-10-27 CLS Therapeutics Limited TREATMENT OF DISEASES BY LIVER EXPRESSION OF AN ENZYME WITH DESOXYRIBONUCLEASE (DNASE) ACTIVITY
JP7384906B2 (ja) * 2018-07-09 2023-11-21 ジーアールオー・バイオサイエンシズ・インコーポレイテッド 非標準アミノ酸含有組成物とその使用
WO2020106709A1 (en) * 2018-11-19 2020-05-28 Gro Biosciences Inc. Human dnase for lung disease
US11744925B2 (en) * 2019-01-28 2023-09-05 Microvention, Inc. Coatings
US12478684B2 (en) * 2019-04-11 2025-11-25 Northeastern University Oligonucleotide-polymer miktoarm conjugates and methods of use
WO2021046307A1 (en) * 2019-09-04 2021-03-11 North Carolina State University Hybridized poly(amidoamine)-amino acid dendrimers
US20250228954A1 (en) * 2020-01-24 2025-07-17 Sarepta Therapeutics, Inc. Designing Antisense Oligonucleotide Delivery Peptides by Interpretable Machine Learning
US20230346829A1 (en) * 2020-05-11 2023-11-02 Revir, Inc. Compositions and methods for treating viral infections
EP4149482A4 (en) * 2020-05-13 2024-05-22 Glycosyn LLC 2'-FUCOSYLLACTOSE FOR THE PREVENTION AND TREATMENT OF CORONAVIRUS-INDUCED INFLAMMATION
US11331329B2 (en) 2020-05-13 2022-05-17 Glycosyn LLC Fucosylated oligosaccharides for prevention of coronavirus infection
WO2022026689A1 (en) 2020-07-30 2022-02-03 Microvention, Inc. Antimicrobial coatings
US20220040315A1 (en) * 2020-08-09 2022-02-10 Fulu Labs Corporation Nuclease-dendrimer formulations for covid-19 and broad-spectrum antiviral therapy and prophylaxis
US20230263900A1 (en) * 2020-08-31 2023-08-24 Starpharma Pty Ltd. Dendrimer-drug conjugate
CN117651550A (zh) * 2021-07-02 2024-03-05 奥古尔·米尔扎尤索夫娜·穆萨哈诺娃 用于预防SARS-CoV-2感染的药物
CN114250208B (zh) * 2021-12-22 2023-07-25 武汉瀚海新酶生物科技有限公司 耐高盐高活性DNase I突变体的制备及应用
WO2024092230A2 (en) * 2022-10-28 2024-05-02 The Regents Of The University Of California Recombinant enhanced antiviral restrictors

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5115096A (en) 1988-04-15 1992-05-19 Oncogen Amphiregulin: a bifunctional growth modulating glycoprotein
EP0460021A4 (en) * 1989-02-23 1992-08-26 Seragen, Inc. Chimeric toxin
US5629173A (en) * 1990-08-09 1997-05-13 Genentech, Inc. Methods of use of serine protease variants having peptide ligase activity
US5989886A (en) * 1991-01-02 1999-11-23 The Johns Hopkins University Method for the inhibition and prevention of viral replication using fusions of a virus protein and a destructive enzyme
US5792640A (en) * 1992-04-03 1998-08-11 The Johns Hopkins University General method to clone hybrid restriction endonucleases using lig gene
US5484589A (en) 1992-04-20 1996-01-16 Rufeld, Inc. Anti-viral methods using RNAse and DNAse
US5503973A (en) 1992-05-29 1996-04-02 The Regents Of The University Of California Method for inhibition of viral morphogenesis
WO1995000170A1 (en) 1993-06-24 1995-01-05 Rufeld, Inc. Inhibition of human immunodeficiency virus reproduction by deoxyribonuclease i
RU2066551C1 (ru) 1994-03-23 1996-09-20 Институт нефтехимического синтеза РАН Способ получения инсулинсодержащих полимерных гидрогелей
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5997861A (en) * 1994-10-31 1999-12-07 Burstein Laboratories, Inc. Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
US7432048B2 (en) * 1996-11-29 2008-10-07 Third Wave Technologies, Inc. Reactions on a solid surface
US5739512A (en) 1996-05-30 1998-04-14 Sun Microsystems, Inc. Digital delivery of receipts
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6280991B1 (en) 1997-10-15 2001-08-28 Wisconsin Alumni Research Foundation Engineered cytotoxic ribonclease
US6017537A (en) * 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
WO2000037658A2 (en) 1998-12-21 2000-06-29 Genencor International, Inc. Chemically modified enzymes with multiple charged variants
US6485718B1 (en) 1999-04-13 2002-11-26 Pharmacia Corporation Site specific ligation of proteins to synthetic particles
HUP0201425A3 (en) * 1999-04-23 2006-07-28 Hadasit Med Res Service Conjugate having a cleavable linkage for use in a liposome
WO2001013957A2 (en) 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US20010053521A1 (en) * 1999-09-27 2001-12-20 Kreimer David I. Amplification of analyte detection by substrates having particle structures with receptors
US6312956B1 (en) 1999-10-01 2001-11-06 Vanderbilt University Nuclear targeted peptide nucleic acid oligomer
US6962906B2 (en) 2000-03-14 2005-11-08 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US7091026B2 (en) 2001-02-16 2006-08-15 University Of Iowa Research Foundation Artificial endonuclease
US20030125241A1 (en) 2001-05-18 2003-07-03 Margit Wissenbach Therapeutic uses of LNA-modified oligonucleotides in infectious diseases
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
GB0126251D0 (en) * 2001-11-01 2002-01-02 Imp College Innovations Ltd Methods
EA008940B1 (ru) 2002-09-13 2007-10-26 Репликор, Инк. Антивирусные олигонуклеотиды, не связанные с комплементарностью последовательностей
US20040147027A1 (en) * 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
JP2008505853A (ja) * 2004-04-13 2008-02-28 クインテセンス バイオサイエンシーズ インコーポレーティッド 細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
EP1734991A4 (en) * 2004-04-14 2012-10-24 Avirid Inc COMPOSITIONS COMPRISING MODIFIED NUCLEASES DIRECTED AGAINST VIRAL NUCLEIC ACIDS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES

Also Published As

Publication number Publication date
AU2005247298B8 (en) 2011-03-10
WO2005115444A3 (en) 2006-12-14
US20090047272A1 (en) 2009-02-19
EP1734991A2 (en) 2006-12-27
WO2005115444A2 (en) 2005-12-08
AU2005247298A1 (en) 2005-12-08
US9592277B2 (en) 2017-03-14
US10335372B2 (en) 2019-07-02
AU2011200602A1 (en) 2011-03-03
EP1734991A4 (en) 2012-10-24
CA2604243C (en) 2015-11-24
AU2005247298B2 (en) 2010-11-11
AU2011200602A2 (en) 2011-05-26
CA2604243A1 (en) 2005-12-08
US20170209376A1 (en) 2017-07-27
JP2007532666A (ja) 2007-11-15

Similar Documents

Publication Publication Date Title
EP1734991A4 (en) COMPOSITIONS COMPRISING MODIFIED NUCLEASES DIRECTED AGAINST VIRAL NUCLEIC ACIDS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES
IL188966A0 (en) Targeted intrgration and expression of exogenous nucleic acid sequences
IL180600A0 (en) Compositions and methods of use for treatment of mammalian diseases
EP1933880A4 (en) OLIGORIBONUCLEOTIDES AND METHODS OF USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES
PL2578685T3 (pl) Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
IL189528A0 (en) Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
IL176960A0 (en) Compositions and methods of treatment for inflammatory diseases
IL189025A0 (en) Use of heat shock to treat ocular disease
IL197804A0 (en) Compositions for the trearment of hepatitis c and methods for using compositions for the treatment of hepatitis c
EP2414545A4 (en) COMPOSITIONS AND METHODS FOR THE PREPARATION OF NUCLEIC ACIDS
EP1804813A4 (en) FORMULATIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP2049899A4 (en) METHOD FOR THE PREVENTION AND TREATMENT OF DISEASES
EP2061788A4 (en) NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ACTIVATED LYMPHOCYTES
GB0514909D0 (en) Methods of nucleic acid amplification and sequencing
GB0811801D0 (en) Compositions and methods relating to treatment of cancer and infectious diseases
EP1791831A4 (en) METHOD FOR THE TREATMENT OF DISEASES AND DISORDERS BY TARGETING MULTIPLE KINASES
AU2003225281A8 (en) Materials and methods for prevention and treatment of rna viral diseases
IL179796A0 (en) Use of imatinib to treat liver disorders and viral infections
EP1838856A4 (en) PROCESS FOR DELIVERING NUCLEIC ACIDS TO PERIPHERAL NEURONS
SI1919290T1 (sl) Postopki in proizvodi za zdravljenje bolezni
PT2572724T (pt) Tratamento de fibroses e doenças hepáticas
PL1818064T3 (pl) Sposoby traktowania skóry w celu wzmocnienia jej leczenia terapeutycznego
HUE026600T2 (hu) Készítmények és eljárások virális hepatitis kezelésére
GB0720997D0 (en) Methods of altering gene expression and methods of treatment utilizing same
IL185616A0 (en) The use of thiophosphonoformic acid and nrtis to treat viral infections